Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Blood (2024) 144 (16): 1689–1698.

https://doi.org/10.1182/blood.2024024952

Published: 2024

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

Jennifer N. Brudno, Jeremiah Karrs, Danielle Natrakul, Nisha Patel, Lekha Mikkilineni, Jennifer Mann, David F. Stroncek, Steven Highfill, Norris Lam, Genevieve C. Fromm, Rashmika Patel, Stefania Pittaluga, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 12731–12732.

https://doi.org/10.1182/blood-2022-157149

Published: 2022

Journal Articles

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Katherine Weissler, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Hao-Wei Wang, Constance M. Yuan, David F. Stroncek, Steven Highfill, Micaela Ganadan, Rashmika Patel, Steven A Rosenberg, James N. Kochenderfer

Blood (2022) 140 (Supplement 1): 7433–7434.

https://doi.org/10.1182/blood-2022-159156

Published: 2022

Journal Articles

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Lekha Mikkilineni, Elisabet E. Manasanch, Danielle Natrakul, Jennifer N. Brudno, Jennifer Mann, Stephanie L Goff, James C Yang, Norris Lam, Irina Maric, Maryalice Stetler-Stevenson, Hao-Wei Wang, Constance M. Yuan, Tyler Lowe, David F. Stroncek, Steven Highfill, Rashmika Patel, Micaela Ganadan, Steven A Rosenberg, James N. Kochenderfer

Blood (2021) 138 (Supplement 1): 3837.

https://doi.org/10.1182/blood-2021-152688

Published: 2021

Journal Articles

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-138839

Published: 2020

Journal Articles

Infectious Complications Associated with CAR T-Cell Therapy

Lekha Mikkilineni, MD, Shilpa Shahani, MD, Bonnie Yates, NP, Seth M. Steinberg, PhD, Tara Palmore, MD, Veronique Nussenblatt, MD, Daniel W. Lee, MD, Rosandra N. Kaplan, MD, Crystal L. Mackall, MD, Terry J. Fry, MD, Juan Gea-Banacloche, MD, Theresa Jerussi, James N. Kochenderfer, MD, Nirali N. Shah, MD

Blood (2019) 134 (Supplement_1): 4449.

https://doi.org/10.1182/blood-2019-131170

Published: 2019

Journal Articles

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Lekha Mikkilineni, MD, Elisabet E. Manasanch, MD, Norris Lam, BS, Danielle Vanasse, BS, Jennifer N. Brudno, MD, Irina Maric, MD MSci, Jeremy J. Rose, MS, Maryalice Stetler-Stevenson, MD PhD, Hao-Wei Wang, MD PhD, Constance M. Yuan, MD PhD, David F. Stroncek, MD, Jennifer Mann, CRNP, Micaela Ganadan, BSN, RN, Rashmika Patel, Nathan Trinklein, PhD, Ben Buelow, MD PhD, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2019) 134 (Supplement_1): 3230.

https://doi.org/10.1182/blood-2019-129088

Published: 2019

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

Chimeric antigen receptor T-cell therapies for multiple myeloma

Lekha Mikkilineni, James N. Kochenderfer

Blood (2017) 130 (24): 2594–2602.

https://doi.org/10.1182/blood-2017-06-793869

Published: 2017

Journal Articles

Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation

Lekha Mikkilineni, MD, Kinjal Parikh, MD, Fern Martin, MD, Dolores Grosso, R.N., CRNP, DNP, Benjamin Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne E. Filicko-O'Hara, MD

Blood (2015) 126 (23): 4394.

https://doi.org/10.1182/blood.V126.23.4394.4394

Published: 2015

Journal Articles

Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy

Kinjal Parikh, MD, Lekha Mikkilineni, MD, Fern Martin, MD, Dolores Grosso, R.N., CRNP, DNP, Benjamin Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2015) 126 (23): 2023.

https://doi.org/10.1182/blood.V126.23.2023.2023

Published: 2015

Journal Articles

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Fern Martin, MD, Lekha Mikkilineni, MD, Kinjal Parikh, MD, Dolores Grosso, DNP, Benjamin E Leiby, PhD, Onder Alpdogan, MD, Matthew Carabasi, MD, Margaret Kasner, MD, Thomas R. Klumpp, MD, Ubaldo Martinez-Outschoorn, MD, Manish Sharma, MD, Mark Weiss, MD, John L. Wagner, MD, Neal Flomenberg, MD, Joanne Filicko-O'Hara, MD

Blood (2015) 126 (23): 3220.

https://doi.org/10.1182/blood.V126.23.3220.3220

Published: 2015

NARROW

A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Transient Responses and Significant Toxicities Due to Cytopenias and Rashes with Anti-CD30 CAR T Cells for CD30-Expressing Lymphomas: Results of a Phase I Clinical Trial

T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

Infectious Complications Associated with CAR T-Cell Therapy

T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Chimeric antigen receptor T-cell therapies for multiple myeloma

Smoking History and Pre-Transplant Pulmonary Function Predict Post-Transplant Respiratory Failure, Acute Renal Failure Requiring Dialysis and 100-Day Mortality in Allogeneic Bone Marrow Transplantation

Moderate Reduction in LVEF Is Associated with an Increased Risk of Post-HSCT Symptomatic Cardiomyopathy

Creatinine > 1.5 Mg/Dl and MDS Diagnosis Predicts Poor Outcome Following HSCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only